M42, an Abu Dhabi-based tech-enabled healthcare company, has signed a Memorandum of Cooperation (MoC) with Japan’s National Institutes for Quantum Science and Technology (QST) in order to share research around carbon ion therapy, an advanced form of radiation therapy used to treat cancer.
The two bodies will leverage their combined experience to further their understanding and knowledge of the technology.
The alliance is part of M42’s commitment to delivering world-class patient-centric care enabled by advanced technologies and innovative solutions.
Mr. Shigeo Koyasu, President of QST, commented that, “It is wonderful to start research cooperation with M42. This MoC will promote widespread use of carbon ion radiotherapy and help build a healthy and long-lived society with zero cancer deaths.”
Carbon ion therapy has gained significant interest globally due to its advantageous physical and radiobiologic properties compared to photon-based therapy.
It allows dose escalation to tumors while reducing radiation dose to adjacent normal tissues. There are currently 16 centers around the world treating with carbon ion radiotherapy. To date, it has been studied and proven effective for many types of malignancies, as per the statement.
Mr. Hasan Jasem Al Nowais, Group Chief Executive Officer and Managing Director of M42 said that, “We are honored to sign this MoC with QST, the leaders in charged particle radiotherapy, marking a pivotal milestone in our quest to expand clinical research in this field.”
“By working hand in hand, we are confident that our collaboration will enable optimal cancer care, further potential clinical indications for carbon ion therapy, and shape the future of healthcare in the region and beyond,” Mr. Al Nowais added.
